↓ Skip to main content

Phase 2 study of pembrolizumab in patients with advanced rare cancers

Overview of attention for article published in Journal for Immunotherapy of Cancer, March 2020
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Citations

dimensions_citation
67 Dimensions

Readers on

mendeley
59 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase 2 study of pembrolizumab in patients with advanced rare cancers
Published in
Journal for Immunotherapy of Cancer, March 2020
DOI 10.1136/jitc-2019-000347
Pubmed ID
Authors

Aung Naing, Funda Meric-Bernstam, Bettzy Stephen, Daniel D Karp, Joud Hajjar, Jordi Rodon Ahnert, Sarina A Piha-Paul, Rivka R Colen, Camilo Jimenez, Kanwal P Raghav, Renata Ferrarotto, Shi-Ming Tu, Matthew Campbell, Linghua Wang, Sarjeel H Sabir, Coya Tapia, Chantale Bernatchez, Michael Frumovitz, Nizar Tannir, Vinod Ravi, Saria Khan, Jeane M Painter, Abulrahman Abonofal, Jing Gong, Anas Alshawa, Lacey M McQuinn, Mingxuan Xu, Sara Ahmed, Vivek Subbiah, David S Hong, Shubham Pant, Timothy A Yap, Apostolia M Tsimberidou, Ecaterina E Ileana Dumbrava, Filip Janku, Siqing Fu, Richard M Simon, Kenneth R Hess, Gauri R Varadhachary, Mouhammed Amir Habra

Twitter Demographics

The data shown below were collected from the profiles of 68 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 59 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 9 15%
Other 9 15%
Student > Bachelor 8 14%
Researcher 5 8%
Student > Ph. D. Student 4 7%
Other 6 10%
Unknown 18 31%
Readers by discipline Count As %
Medicine and Dentistry 24 41%
Biochemistry, Genetics and Molecular Biology 4 7%
Nursing and Health Professions 2 3%
Environmental Science 1 2%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Other 7 12%
Unknown 20 34%

Attention Score in Context

This research output has an Altmetric Attention Score of 120. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 November 2022.
All research outputs
#285,826
of 22,512,774 outputs
Outputs from Journal for Immunotherapy of Cancer
#55
of 2,847 outputs
Outputs of similar age
#8,672
of 342,057 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#2
of 147 outputs
Altmetric has tracked 22,512,774 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,847 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.5. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,057 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 147 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.